Show simple item record

AuthorTomic, Kresimir
AuthorKrpina, Kristina
AuthorBaticic, Lara
AuthorSamarzija, Miroslav
AuthorVranic, Semir
Available date2024-06-11T11:39:18Z
Publication Date2024-03-25
Publication NameJournal of Drug Targeting
Identifierhttp://dx.doi.org/10.1080/1061186X.2024.2332733
CitationTomic, K., Krpina, K., Baticic, L., Samarzija, M., & Vranic, S. (2024). Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report. Journal of Drug Targeting, 1-11.
ISSN1061-186X
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85189545347&origin=inward
URIhttp://hdl.handle.net/10576/56077
AbstractHistologic transformation to small cell lung cancer (tSCLC) is a rare but increasingly recognised mechanism of acquired resistance to tyrosine kinase inhibitors (TKI) in patients with epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). Beyond its acknowledged role in TKI resistance, histologic transformation to SCLC might be an important, yet under-recognised, mechanism of resistance in NSCLC treated with immunotherapy. Our review identified 32 studies that investigated tSCLC development in patients with EGFR-mutated NSCLC treated with TKI therapy and 16 case reports of patients treated with immunotherapy. It revealed the rarity of tSCLC, with a predominance of EGFR exon 19 mutations and limited therapeutic options and outcomes. Across all analysed studies in EGFR-mutated NSCLC treated with TKI therapy, the median time to tSCLC development was ∼17 months, with a median overall survival of 10 months. Histologic transformation of EGFR-mutated NSCLC to SCLC is a rare, but challenging clinical problem with a poor prognosis. A small number of documented cases of tSCLC after immunotherapy highlight the need for rebiopsies at progression to diagnose this potential resistance mechanism. Further research is needed to better understand the mechanisms underlying this phenomenon and to develop more effective treatment strategies for patients with tSCLC.
Languageen
PublisherTaylor & Francis
Subjectepidermal growth factor receptor
histologic transformation
immunotherapy
Non-small cell lung cancer
small cell lung cancer
tyrosine kinase inhibitors
TitleComprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report
TypeArticle
Pagination1-11
ESSN1029-2330
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record